Status:
COMPLETED
Stellate Ganglion Block (SGB) for COVID-19 Acute Respiratory Distress Syndrome (ARDS)
Lead Sponsor:
West Virginia University
Conditions:
Acute Respiratory Distress Syndrome
COVID-19
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
The purpose of this study is to understand if it is safe and useful to perform SGB (Stellate Ganglion Block) in patients who have severe lung injury Acute Respiratory Distress Syndrome (ARDS) due to C...
Detailed Description
Primary Aim: • To determine safety of stellate ganglion block (SGB) in ARDS Secondary Aim: * To determine efficacy of SGB in slowing the progression of ARDS
Eligibility Criteria
Inclusion
- Subjects age 18 to 80
- Subjects with PCR documented diagnosis of COVID-19 ARDS requiring critical care and transfer to intensive care unit
- Bilateral opacities consistent with pulmonary edema must be present and may be detected on CT or chest radiograph
Exclusion
- Subjects with pre-existing cardiac failure
- Hemodynamic Instability
- Subject on Extracorporeal membrane oxygenation (ECMO)
- Anatomical inability to do a stellate block
Key Trial Info
Start Date :
April 24 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2020
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT04402840
Start Date
April 24 2020
End Date
December 31 2020
Last Update
April 25 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
West Virginia University Rockefeller Neuroscience Institute
Morgantown, West Virginia, United States, 26506